WATERTOWN, Mass.— Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced the pricing of its initial public offering of 3,500,000 shares of common stock at a public offering price of $16.00 per share, before deducting underwriting discounts and commissions. All of the common stock is being offered by Lyra. The offering is expected to close on May 5, 2020, subject to customary closing conditions. In addition, Lyra has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The gross proceeds of the offering are expected to be $56.0 million, excluding any exercise of the underwriters’ option.

Synaptive Medical received an FDA clearance for its slightly miniaturized and more-manageable MRI system, the second such device to receive the agency’s green light in as many months.

Boston-based resTORbio and Menlo Park, California-based Adicet Bio announced plans to combine into a single company. The merged company will focus on developing Adicet’s off-the-shelf allogeneic gamma delta T-cell therapies for cancer and other indications.

The team that developed Zolgensma is back for round two. A group of former AveXis executives and investors unveiled a new gene therapy company, and they’re wasting no time. With 15 programs, $30 million in seed funding and an “unrivaled” partnership with UT Southwestern Medical Center, Taysha Gene Therapies plans to be in the clinic by the end of the year.

Roche has presented more of the data that could enable it to challenge Biogen and Novartis for the spinal muscular atrophy (SMA) market. The readout shows 29% of infants with the most severe form of the disease could briefly sit without support after taking risdiplam, adding to evidence that Roche has a viable challenger for the market.

Compugen’s anti-PVRIG antibody showed early promise in a small phase 1 study, curbing tumor growth in more than two-thirds of patients with various solid tumors who had exhausted all other treatment options. The treatment did similarly in tandem with Bristol Myers Squibb’s PD-1 blocker Opdivo, stopping tumor growth in three-quarters of patients.

In 2018, Rosana Kapeller left Nimbus Therapeutics, the company she built from the ground up, “to do something different.” Two years and a stint at GV later, she’s unveiling that something: Rome Therapeutics, a new biotech startup looking to drug parts of the human genome previously spurned as “junk DNA.”

GlaxoSmithKline has posted some updated though underwhelming and “clinically meaningful” data from a PD-1 inhibitor it got via its $5 billion Tesaro buyout.

Takeda has allied with ProThera Biologics to develop a plasma-derived inter-alpha inhibitor proteins (IAIP) therapy for use in acute inflammatory conditions. The deal advances Takeda’s efforts to extract value from the plasma-derived therapy unit it acquired in its $62 billion takeover of Shire.

Two years ago, Accent Therapeutics got off a $40 million series A to target RNA-modifying proteins in cancer; now, in the middle of a pandemic, it’s still managed to bring in a respectable $63 million second funding round.